Indivior PLC (INDV) AI Stock Analysis

Indivior PLC, headquartered in North Chesterfield, Virginia, is a global leader in developing, manufacturing, and distributing buprenorphine-based prescription drugs. These medications treat opioid dependence and co-occurring disorders across the United States, the United Kingdom, and international markets. The company also creates treatments for substance use disorders, serious mental illnesses, and opioid overdose. Its core commercial portfolio features SUBLOCADE and SUBUTEX PRO extended-release monthly injections, alongside SUBOXONE sublingual film and tablets, and SUBUTEX sublingual tablets. In addition, Indivior is advancing pipeline candidates such as INDV-2000 for opioid use disorder and INDV-1000 for alcohol use disorder, while collaborating with partners including Alar Pharmaceuticals Inc. and Click Therapeutics.

Indivior expanded annual revenue from $791.0M in FY2021 to $1.24B in FY2025, achieving a 5-year revenue compound annual growth rate of 13.9%. Annual net income shifted from $205.0M in FY2021 to losses of -$44.0M in FY2022 and -$129.0M in FY2023, before recovering to $2.0M in FY2024 and $210.0M in FY2025. Gross margin stood at 80.1% in FY2025, while operating margin reached 21.4%. In the trailing twelve months, revenue totaled $1.33B with a net profit margin of 26.8% and diluted EPS of $2.79. For the latest quarter ended June 30, 2026, quarterly revenue grew 13.6% year-over-year and quarterly earnings grew 600.0%.

As of June 30, 2026, Indivior held $222.0M in cash and short-term investments against total debt of $509.0M, resulting in net debt of $287.0M. The company reported total assets of $1.23B and a current ratio of 0.84. Shareholders' equity was -$208.0M, reflecting negative equity. Operating cash flow for FY2025 was -$27.0M, while free cash flow was -$94.0M. Capital expenditures absorbed $67.0M during FY2025, and share buybacks totaled $11.0M, contributing to a 5-year share count change of -8.2%.

At a last close of $32.45, Indivior had a market capitalization of $3.83B and an enterprise value of $4.52B. The stock traded at a trailing P/E of 11.6x and a forward P/E of 9.5x, below the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. Its price-to-sales ratio was 2.9x compared to the peer median of 4.1x, while its EV-to-EBITDA stood at 10.3x versus the peer median of 12.0x. Over the past year, Indivior gained 31.4%, outperforming the S&P 500 (SPY) return of 16.8%, and delivered a 5-year return of 104.7% versus 83.0% for the index.

Wall Street coverage includes 3 Strong Buy ratings and 1 Buy rating, with no Hold, Sell, or Strong Sell recommendations. The mean price target of $49.00 implies upside of 51.0% over the last close of $32.45. For the fiscal year ending December 31, 2026, consensus estimates project EPS of $4.41 on revenue of $1.33B, representing EPS growth of 76.3%. Next fiscal year estimates project EPS of $4.88 on revenue of $1.40B. The company beat EPS estimates in each of the last 4 quarters, with its next earnings date scheduled for October 29, 2026.

This page is an AI-written research summary of Indivior PLC (INDV). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: INDV income statement, INDV balance sheet, INDV key metrics, INDV analyst forecast, INDV chart. See the INDV stock overview for the latest quote and news.